Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(pyrimidinylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below:
wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.”
以下为取代的1,3-二烷基-2,4-二氧杂-6-(
嘧啶基
氨基)-1,2,3,4-四氢
嘧啶-5-羟
肟酸化合物,其中变量如本文所定义,以及其制药组合物,用作MEK激酶
抑制剂。